Becton, Dickinson and Company (BIT:1BDX)
Italy · Delayed Price · Currency is EUR 152.95
0.00 (0.00%)
At close: Jul 24, 2025, 5:30 PM CET
Revenue by Product
Fiscal year is October - September.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2012 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 | Sep '20 Sep 30, 2020 | 2012 - 2019 |
Medication Delivery Solutions | 4.43B | Log In | Log In | Log In | Log In | Upgrade |
Medication Delivery Solutions Growth | 3.87% | Log In | Log In | Log In | Log In | Upgrade |
Pharmaceutical Systems | 2.27B | Log In | Log In | Log In | Log In | Upgrade |
Pharmaceutical Systems Growth | 0.44% | Log In | Log In | Log In | Log In | Upgrade |
Biosciences | 1.51B | Log In | Log In | Log In | Log In | Upgrade |
Biosciences Growth | -3.41% | Log In | Log In | Log In | Log In | Upgrade |
Other | -67.00M | Log In | Log In | Log In | Log In | Upgrade |
Other Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Medication Management Solutions | 3.30B | Log In | Log In | Log In | Log In | Upgrade |
Medication Management Solutions Growth | 10.49% | Log In | Log In | Log In | Log In | Upgrade |
Surgery | 1.49B | Log In | Log In | Log In | Log In | Upgrade |
Surgery Growth | 1.33% | Log In | Log In | Log In | Log In | Upgrade |
Peripheral Intervention | 1.93B | Log In | Log In | Log In | Log In | Upgrade |
Peripheral Intervention Growth | 1.99% | Log In | Log In | Log In | Log In | Upgrade |
Urology and Critical Care | 1.55B | Log In | Log In | Log In | Log In | Upgrade |
Urology and Critical Care Growth | 4.09% | Log In | Log In | Log In | Log In | Upgrade |
Medical | 10.07B | Log In | Log In | Log In | Log In | Upgrade |
Medical Growth | 11.41% | Log In | Log In | Log In | Log In | Upgrade |
Life Sciences | 5.19B | Log In | Log In | Log In | Log In | Upgrade |
Life Sciences Growth | -0.08% | Log In | Log In | Log In | Log In | Upgrade |
Interventional | 4.98B | Log In | Log In | Log In | Log In | Upgrade |
Interventional Growth | 2.45% | Log In | Log In | Log In | Log In | Upgrade |
Other | -67.00M | Log In | Log In | Log In | Log In | Upgrade |
Other Growth | - | Log In | Log In | Log In | Log In | Upgrade |
EBIT by Product
Fiscal year is October - September.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2012 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 | Sep '20 Sep 30, 2020 | 2012 - 2019 |
Other | -2.88B | Log In | Log In | Log In | Log In | Upgrade |
Other Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Medical Operating Income | 2.74B | Log In | Log In | Log In | Log In | Upgrade |
Medical Operating Income Growth | 31.39% | Log In | Log In | Log In | Log In | Upgrade |
Life Sciences Operating Income | 1.60B | Log In | Log In | Log In | Log In | Upgrade |
Life Sciences Operating Income Growth | 1.55% | Log In | Log In | Log In | Log In | Upgrade |
Other | -2.88B | Log In | Log In | Log In | Log In | Upgrade |
Other Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Interventional Operating Income | 1.42B | Log In | Log In | Log In | Log In | Upgrade |
Interventional Operating Income Growth | 17.19% | Log In | Log In | Log In | Log In | Upgrade |